Urogen Pharma (NASDAQ:URGN) Posts Earnings Results, Misses Estimates By $0.14 EPS

Urogen Pharma (NASDAQ:URGN) announced its quarterly earnings data on Wednesday. The company reported ($0.03) earnings per share for the quarter, missing analysts’ consensus estimates of $0.11 by ($0.14), FiscalAI reports. The company had revenue of $89.00 million for the quarter, compared to analysts’ expectations of $89.92 million.

Here are the key takeaways from Urogen Pharma’s conference call:

• ZUSDURI revenue reached $68 million, up 35% sequentially. Prescribers increased to 662, repeat prescribers rose to 331, and management expects further quarter-over-quarter revenue growth in Q4 despite typical holiday seasonality.
• Management said the launch remains early, with broad adoption still developing: repeat prescribers were 50% of total writers, and the company estimated only a little over 10% of its core target urologists had prescribed ZUSDURI. It plans to expand patient-awareness efforts around mid-2027, while citing reimbursement confidence and practice workflows as adoption hurdles.
• JELMYTO revenue was $21 million, down from $22 million in Q2, and full-year revenue guidance was revised to approximately $90 million. The company cited a one-time $1.5 million gross-to-net adjustment and competition from clinical trials that is weighing on patient starts.
• The FDA accepted UGN-103’s NDA and set a June 14, 2027 PDUFA date; UroGen plans a potential launch in 2028, subject to approval and a permanent J-code. The company also expects to complete UGN-104 enrollment by year-end or early 2027, and has dosed the first patient in the UGN-501 Phase I trial.
• UroGen reported $90.5 million in cash and marketable securities, plus $117 million in accounts receivable, and management expects profitability and positive cash flow in Q4 2026. Operating expenses are now expected toward the upper end of the $260 million–$270 million guidance range.

Urogen Pharma Stock Down 16.9%

Urogen Pharma stock traded down $5.80 during midday trading on Wednesday, reaching $28.60. The company’s stock had a trading volume of 2,439,524 shares, compared to its average volume of 848,646. Urogen Pharma has a fifty-two week low of $16.50 and a fifty-two week high of $50.81. The company has a market cap of $1.40 billion, a P/E ratio of -14.45 and a beta of 1.68. The business has a 50-day simple moving average of $39.96 and a 200-day simple moving average of $31.42.

Insiders Place Their Bets

In related news, insider Mark Schoenberg sold 871 shares of the company’s stock in a transaction that occurred on Tuesday, September 8th. The stock was sold at an average price of $42.92, for a total value of $37,383.32. Following the completion of the transaction, the insider directly owned 59,882 shares of the company’s stock, valued at $2,570,135.44. This represents a 1.43% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, General Counsel Jason Smith sold 1,519 shares of the stock in a transaction that occurred on Tuesday, September 8th. The shares were sold at an average price of $42.54, for a total transaction of $64,618.26. Following the completion of the transaction, the general counsel owned 53,141 shares in the company, valued at $2,260,618.14. This represents a 2.78% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 65,269 shares of company stock valued at $3,037,646 in the last ninety days. Insiders own 4.80% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms have recently weighed in on URGN. Jefferies Financial Group reaffirmed a “buy” rating and set a $56.00 price objective on shares of Urogen Pharma in a research report on Thursday, September 10th. TD Cowen lifted their target price on Urogen Pharma from $50.00 to $60.00 and gave the company a “buy” rating in a report on Wednesday, August 5th. The Goldman Sachs Group reissued a “neutral” rating and set a $44.00 target price on shares of Urogen Pharma in a research note on Wednesday, July 15th. HC Wainwright restated a “buy” rating and set a $75.00 price target on shares of Urogen Pharma in a report on Monday, October 19th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Urogen Pharma in a report on Thursday, October 15th. Eight analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $52.38.

Urogen Pharma Company Profile

UroGen Pharma Ltd. (NASDAQ: URGN) is a biopharmaceutical company focused on developing and commercializing treatments for cancers of the urinary tract. The company’s therapies are designed to deliver medicines directly to the affected area, with the goal of improving drug exposure while limiting systemic side effects.

UroGen’s primary commercial product is Jelmyto, a mitomycin-based treatment approved in the United States for adults with low-grade upper tract urothelial cancer. Jelmyto uses UroGen’s proprietary RTGel technology, which forms a gel in the urinary tract and enables the sustained local release of mitomycin.

The company has also developed UGN-102, an investigational mitomycin-based reverse thermal gel intended for the treatment of low-grade, intermediate-risk non-muscle-invasive bladder cancer.